# Atrial Fibrillation: In Search for the Optimal Target for Rate Control

Study · id `cardio:ct-nct07135258` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07135258](<https://clinicaltrials.gov/study/NCT07135258>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07135258

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07135258. Randomized; triple masking; primary purpose treatment. Start 2025-10-01 (anticipated); primary completion 2027-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07135258, source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)
- Planned start: 2025-10-01 (anticipated) (ClinicalTrials.gov record NCT07135258, source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)
- Primary completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT07135258, source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)
- Completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT07135258, source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT07135258, source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07135258-2025-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atrial Fibrillation: In Search for the Optimal Target for Rate Control
- Acronym: STRICT-4-FUN
- Condition: Atrial Fibrillation (Permanent)
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): Ivabradine + Usual Care
- Intervention (Drug): Placebo + usual care
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: 896c9987f77913f9a714b81b28d4bdf54720aba5b7b109d9c09a9d35073d9520
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
